Belumosudil treatment
Preclinical
Belumosudil treatment is one of 3 therapeutic programs targeting Hematopoietic Stem Cell Transplantation (HSCT). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in Hematopoietic Stem Cell Transplantation (HSCT)
#DrugCompanyPhaseTrials
1Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Teprenone
EisaiPreclinical
Belumosudil treatment
FFirst Affiliated Hospital of Zhejiang University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Belumosudil treatment. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]